The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

Completed

Conditions studied: Rheumatoid Arthritis

In brief

The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).

Key facts

Study ID

NCT03331393

Run by

Bristol-Myers Squibb

People needed

265

Starts

2017-03-16

Expected to finish

2019-01-17

Last updated by the study team

2022-07-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age at enrollment
• Confirmed diagnosed with RA
• Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site

You may not qualify if…

• Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels
• Was followed at the site for less than 1 year since biologic treatment initiation
• Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Local Institution — Beverly Hills, California, United States
• Local Institution - 0005 — Gainesville, Georgia, United States
• Local Institution — Coeur d'Alene, Idaho, United States
• Local Institution - 0007 — Eagan, Minnesota, United States
• Medication Management, LLC — Greensboro, North Carolina, United States
• Local Institution — Myrtle Beach, South Carolina, United States
• Local Institution — Richland, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.